- Home
- FBRX vs GGN Comparison
FBRX vs GGN Comparison
Compare FBRX & GGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBRX | GGN |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 899.4M | 877.0M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | FBRX | GGN |
|---|---|---|
| Price | $50.73 | $4.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $67.00 | N/A |
| AVG Volume (30 Days) | ★ 824.3K | 588.1K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.26% |
| EPS Growth | ★ 61.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.25 | $4.41 |
| 52 Week High | $52.15 | $5.88 |
Technical Indicators
Market Signals| Indicator | FBRX | GGN |
|---|---|---|
| Relative Strength Index (RSI) | 84.50 | 39.95 |
| Support Level | $24.72 | $4.75 |
| Resistance Level | N/A | $4.96 |
| Average True Range (ATR) | 4.86 | 0.07 |
| MACD | 2.29 | 0.00 |
| Stochastic Oscillator | 95.48 | 23.57 |
Price Performance
Historical ComparisonAbout FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
About GGN GAMCO Global Gold Natural Resources & Income Trust
GAMCO Global Gold Natural Resources & Income Trust is a non-diversified closed-end management investment company. Its primary investment objective is to provide a high current income and capital appreciation as its secondary objective. To achieve its objective, the fund may invest majority of its assets in equity securities of companies principally engaged in the gold and natural resources industries. It also intends to earn income through an option planning of writing (selling) covered call options on equity securities in its portfolio.